STOCK TITAN

Hepion Pharmaceuticals Inc - HEPA STOCK NEWS

Welcome to our dedicated news page for Hepion Pharmaceuticals (Ticker: HEPA), a resource for investors and traders seeking the latest updates and insights on Hepion Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Hepion Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Hepion Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.53%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.94%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.03%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.81%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.57%
Tags
conferences
Hepion Pharmaceuticals Inc

Nasdaq:HEPA

HEPA Rankings

HEPA Stock Data

9.50M
3.86M
0.39%
17.23%
1.45%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Edison

About HEPA

hepion pharmaceuticals, inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the united states. it is involved in developing crv431, a cyclophilin inhibitor that has completed the phase i clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of hepatitis b. the company was formerly known as contravir pharmaceuticals, inc. and changed its name to hepion pharmaceuticals, inc. in july 2019. hepion pharmaceuticals, inc. was incorporated in 2013 and is headquartered in edison, new jersey.